Bernard A. Fox

NeoPharm, Inc. engages in the research, development, and commercialization of drugs for the treatment of various cancers and other diseases. The company has built its drug development program around two proprietary technology platforms, a tumor-targeting toxin platform which includes development for a new indication of Pulmonary Fibrosis, and a novel NeoLipid liposomal drug delivery system. It has advanced five drug product candidates in various stages of clinical and pre clinical development for the treatment of cancer and one drug product candidate in pre-clinical development for treatment of interstitial pulmonary fibrosis and asthma. NeoPharm was founded in May 15, 1900and is headquartered in Lake Bluff, IL.

The International Society for Biological Therapy of Cancer operates as a professional society of influential scientists, academicians, researchers, clinicians, and government representatives. The non-profit company is based in Milwaukee, WI.

UbiVac LLC engages in the research, development and testing of therapeutic immunotherapy strategies to combat cancer and infectious diseases. The company was founded by Bernard A. Fox and Hong-Ming Hu in 2005 and is headquartered in Portland, OR.

InSys Therapeutics, Inc. is a pharmaceutical company that develops and seeks to commercialize innovative pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. The company's product pipeline targeting cancer-supportive care and cancer therapy that it believe can be developed cost efficiently and, if approved, commercialized through a targeted commercial organization. Its supportive care product candidates include Fentanyl SL Spray, a proprietary, fast-acting sublingual fentanyl spray for the treatment of breakthrough cancer pain, and its family of dronabinol product candidates for the treatment of chemotherapy-induced nausea and vomiting and appetite stimulation in AIDS patients. The company was founded by Dr. S. George Kottayil and John N. Kapoor on October 18, 2002 and is headquartered in Phoenix, AZ.

INSYS Therapeutics, Inc. operates as a pharmaceutical company, which develops and commercializes supportive care products. It focuses on utilizing commercial pharmaceutical products that include Subsys, a proprietary sublingual fentanyl spray for BTCP in opioid-tolerant adult patients; and Syndros, a proprietary orally administered liquid formulation of dronabinol for the treatment of CINV and anorexia associated with weight loss in patients with AIDS. The company was founded by John N. Kapoor on June 15, 1990 and is headquartered in Chandler, AZ.

The Oregon Bioscience Association is a non-profit membership association that advocates for and promotes the growth and quality of the bioscience industry in the region. The association is based in Portland, OR. The non-profit company seeks to create opportunities for their members through advocacy, cultivation, education, and group purchasing discounts. The association is affiliated with several other organizations, including the Biotechnology Innovation Organization and the Medical Device Manufacturers Association. The bioscience industry in the region has experienced significant growth, with a bio footprint of $10.70 billion and 47,238 jobs created.